Description: |
The objective of the study is to determine if men with evidence of progressive prostate cancer while on chronic androgen ablation of = 1 year duration will exhibit a clinical response following administration of parenteral testosterone and oral etoposide. Eligible patients will have castrate resistant prostate cancer with minimal disease (rising PSA and = 5 total sites of metastases in bone, lymph node and soft tissue) on continuous castrating androgen ablative therapy for = 1 yr; allowed = 2 prior chemo; allowed = 2 prior second line HT; off antiandrogens for = 6weeks |
Link: |
|
Site: |
Johns Hopkins Hospital |
Principal Investigator: |
Samuel Denmeade, M.D. |
Overview
Content Tools